Nascent Biotech (NBIO) Stock Price, News & Analysis

Company Overview

Nascent Biotech, Inc. is a biotechnology company focused on developing antibody-based therapies for cancer and other serious diseases. The company’s lead product candidate is Pritumumab, a naturally occurring human monoclonal antibody being investigated for its potential to target tumor-associated forms of vimentin, a protein found on the surface of certain cancer cells.

Pritumumab has been studied as a potential treatment for brain tumors, including glioblastoma, as well as other solid tumors. Nascent Biotech’s activities primarily involve preclinical research, clinical development, regulatory work and the advancement of its antibody technology rather than the sale of commercially available pharmaceutical products.

The company’s development efforts have been centered in the United States, where it has pursued regulatory and clinical activities for Pritumumab. Publicly available information about Nascent Biotech’s broader product pipeline, commercial operations and leadership is limited.

Key Stats

• Today's Range: $0.0002 to $0.0002
• 50-Day Range: N/A
• 52-Week Range: $0.00 to $0.13
• Volume: 150 shs
• Average Volume: 39,155 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:NBIO
• CIK: 1622057
• Web: www.nascentbiotech.com
• Phone: (612) 961-5656
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A